Effect Of Ketamine On Patients With Moderate To Severe Depressive Disorder
Not Applicable
- Conditions
- Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features
- Registration Number
- CTRI/2024/07/070304
- Lead Sponsor
- Dayanand Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient seeking treatment at the department of psychiatry, Dayanand Medical College & Hospital (DMCH), Ludhiana.
Both males and females aged 18-65 years.
Primary diagnosis of MDD without psychotic features based on DSM-5.
Diagnosis of moderate-severe MDD defined by MADRS = 20.
Patient who are taking escitalopram 10-20 mg for at least 4 weeks.
Medically stable for study participation
Exclusion Criteria
Any other major psychiatric disorder in patients of Major Depressive Disorder.
History of any known uncontrolled medical condition.
Women who are pregnant or lactating.
Patient who have not given consent for the study.
Untreated hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome measures will be early response and early remission to treatment by improvement in severity of depression on MADRS. Response will be a more than 50% improvement on MADRS scale.Timepoint: reductions in MADRS score will be measured after 4 hrs post ketamine in every session
- Secondary Outcome Measures
Name Time Method Secondary outcome measure will be decrease in suicidal ideation and adverse events in CADSSTimepoint: Patients will undergo prospective observation. Vitals (blood pressure, heart rate etc.,) will be monitored every 5 minutes throughout the time of infusion and every half hourly for 2 hours after infusion.he patients will be discharged after assessing them on Modified Aldrete Score.